Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
0.15% $20.00
America/New_York / 27 apr 2023 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 843.96 mill |
EPS: | -0.960 |
P/E: | -20.83 |
Earnings Date: | Jul 31, 2023 |
SharesOutstanding: | 42.20 mill |
Avg Daily Volume: | 0.678 mill |
RATING 2023-05-02 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/21 | 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -20.83 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.09x |
Company: PE -20.83 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 19.90 - 20.10 ( +/- 0.52%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-04-27 | Paulsen Erik | Sell | 20 627 | Restricted Stock Units |
2023-04-27 | Paulsen Erik | Sell | 700 | Common Stock |
2023-04-27 | Points Jeffrey S. | Sell | 138 957 | Common Stock |
2023-04-27 | Points Jeffrey S. | Sell | 34 051 | Common Stock |
2023-04-27 | Rempe Stephen J. | Sell | 75 659 | Common Stock |
INSIDER POWER |
---|
-76.15 |
Last 100 transactions |
Buy: 675 433 | Sell: 1 911 221 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $20.00 (0.15% ) |
Volume | 0.388 mill |
Avg. Vol. | 0.678 mill |
% of Avg. Vol | 57.21 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.